var data={"title":"Olaparib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Olaparib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/763394?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=olaparib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Olaparib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26730986\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lynparza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46780941\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lynparza</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26641538\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, PARP Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853200\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Olaparib is available as 100 mg and 150 mg tablets and as 50 mg capsules. Do not substitute the 50 mg capsules for the 100 mg or 150 mg tablets on a mg-per-mg basis due to differences in dosing and bioavailability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic, HER2-negative, BRCA-mutated:</b> Oral: <i>Tablets: </i>300 mg twice daily until disease progression or unacceptable toxicity (Robson 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer, advanced (BRCA-mutated):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Capsules:</i> 400 mg twice daily (12 hours apart) until disease progression or unacceptable toxicity (Domchek 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tablets:</i> 300 mg twice daily (12 hours apart) until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer, recurrent (maintenance)</b>: Oral: <i>Tablets:</i> 300 mg twice daily (12 hours apart) until disease progression or unacceptable toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> If a dose is missed, administer the next dose at its scheduled time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Dosage adjustment for concomitant therapy:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>CYP3A inhibitors: </i></b>Avoid concomitant use with moderate or strong CYP3A inhibitors (consider alternative agents with less CYP3A inhibition). If coadministration with a <b>moderate</b> CYP3A inhibitor cannot be avoided, reduce dose to 200 mg twice daily (capsules) or 150 mg twice daily (tablets). If coadministration with a <b>strong</b> CYP3A inhibitor cannot be avoided, reduce dose to 150 mg twice daily (capsules) or 100 mg twice daily (tablets).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>CYP3A inducers:</i></b> Avoid concomitant use with moderate or strong CYP3A4 inducers; a potential for reduced olaparib efficacy exists if moderate CYP3A inducers cannot be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853201\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853202\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 51 to 80 mL/minute: No dosage adjustment necessary; monitor closely for toxicity, as an increase in mean AUC has been observed in patients with mild impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 31 to 50 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Capsules:</i> Reduce dose to 300 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tablets:</i> Reduce dose to 200 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &le;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853203\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate-to-severe impairment (Child-Pugh classes B and C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853204\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Consider therapy interruption or dose reduction if adverse reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Capsules:</i> The recommended first dose reduction is to 200 mg twice daily; if further reduction is required, reduce dose to 100 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tablets:</i> The recommended first dose reduction is to 250 mg twice daily; if further reduction is required, reduce dose to 200 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pneumonitis: Discontinue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secondary AML/MDS: Discontinue</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26730987\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lynparza: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lynparza: 100 mg, 150 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26730985\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853157\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Olaparib is available only through the designated specialty pharmacy Biologics, Inc. For further information on patient assistance, product availability, and prescribing instructions, please refer to the following website:http://myaccess360.com/hcp/reimbursement/Oncology.aspx?product=lynparza or call 1-844-275-2360.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26854741\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lynparza capsules: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206162s008lbl.pdf#page=16&amp;token=ZwRZ/k9ECut1NNzq1UfIWW8sYVeyfCN8aGorxUMruLxX9apP35yx9ZyMyRCUZl+xTuuHUSaupRPTw7lTlm5XIkJX/dSfo9IqWStV1r3Z9SPukS9d3e05LaFIGGr+GkaR&amp;TOPIC_ID=98761\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206162s008lbl.pdf#page=16</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lynparza tablets: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s002lbl.pdf#page=28&amp;token=cr3HO9hP/Kajlx818amaL+zBufG6zw0X9wgpvk56g/vOMQnq03VlMjODoVmprlA3gtOiuEsWTPg8Enf/udubyY9Dkvw3BIuuor96gSrH1kGNBKpL2X16ZnkIh36RopUd&amp;TOPIC_ID=98761\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s002lbl.pdf#page=28</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853207\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer with or without food. Swallow capsules whole; do not chew, dissolve, or open capsule. Do not administer if capsules appear deformed or show evidence of leakage. Swallow tablets whole; do not chew, crush, dissolve, or divide tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Based on a pharmacokinetic study (in tablets), the rate of absorption was slower and the peak exposure was decreased when administered with a high-fat meal; however, the extent of absorption was not affected; nausea and vomiting were reported more frequently when olaparib was administered in a fasted state (Plummer 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib is available as 100 mg and 150 mg tablets and as 50 mg capsules. Due to differences in dosing and bioavailability, do <b>not </b>substitute the 50 mg capsules for the 100 mg or 150 mg tablets on a mg-per-mg basis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133402\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Olaparib may cause reproductive toxicity, teratogenicity, and genotoxicity. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26641540\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, metastatic (BRCA-mutated, HER2-negative):</b> Tablets: Treatment of deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer in patients who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor-positive disease should have received a prior endocrine therapy (or be considered inappropriate for endocrine therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer, advanced (BRCA-mutated):</b> Capsules, tablets: Treatment of deleterious or suspected deleterious germline BRCA-mutated (as detected by an approved test) advanced ovarian cancer in patients who have been treated with 3 or more prior lines of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer, recurrent (maintenance)</b>: Tablets: Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853154\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Olaparib may be confused with niraparib, osimertinib, rucaparib</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lynparza may be confused with Lenvima</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Olaparib is available in tablets and capsules. Dosing and bioavailability differ; do not substitute the capsules and the tablets on a mg-per-mg basis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26970623\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&ge;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (10% to &lt;20%), edema (&lt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;66%), headache (10% to 26%), dizziness (&lt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&lt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypomagnesemia (&lt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (64% to 76%), abdominal pain (43%), vomiting (35% to 43%), diarrhea (28% to 33%), dysgeusia (10% to 27%), dyspepsia (25%), constipation (22%), decreased appetite (21% to 22%), stomatitis (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (10% to &lt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Increased MCV (57% to 85%), decreased absolute lymphocyte count (52% to 67%; grades 3/4: 10% to 17%), decreased white blood cell count (58%; grades 3/4: 4%), decreased neutrophils (25% to 51%; grades 3/4: 7% to 8%), anemia (23% to 44%; grades 3/4: 4% to 20%), decreased platelet count (30% to 42%; grades 3/4: 2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (&le;36%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&le;66%), musculoskeletal pain (21% to 32%), arthralgia (&le;30%), myalgia (&le;30%), back pain (10% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (30% to 45%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (&le;36%), rhinitis (&le;36%), sinusitis (&le;36%), respiratory tract infection (22%), cough (10% to 20%), dyspnea (&lt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&lt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to &le;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension, venous thrombosis (including pulmonary embolism)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, depression, insomnia, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus, xeroderma (including eczema)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash, hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria, urinary incontinence, vulvovaginal disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Myelodysplastic syndrome (acute myeloid leukemia; &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Dermatitis, hypersensitivity reaction, pneumonitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26641541\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to olaparib or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853178\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Anemia, neutropenia, thrombocytopenia, and lymphopenia have been reported. Monitor complete blood counts at baseline and monthly thereafter; do not initiate olaparib until any hematologic toxicity caused by previous chemotherapy has resolved to &le; grade 1. If prolonged hematologic toxicity occurs during therapy, interrupt treatment and monitor blood counts weekly until recovered; if counts do not recover to &le; grade 1 after 4 weeks, further evaluation (including bone marrow and cytogenetic analyses) is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Nausea and vomiting (usually mild to moderate) may commonly occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including rash and dermatitis, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Pneumonitis (including some fatalities) has occurred rarely. Interrupt treatment for new or worsening respiratory symptoms such as cough, dyspnea, fever, wheezing, or radiologic abnormalities; evaluate promptly. Discontinue treatment if pneumonitis is confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) have been reported (rarely) in clinical trials and long-term follow up, mostly in patients with documented BRCA mutation. Most MDS/AML cases were fatal. Additional cases of MDS/AML have been reported in patients treated with olaparib in combination studies. The duration of olaparib therapy prior to development of the secondary cancers ranged from &lt;6 months to &gt;2 years; all patients had received prior chemotherapy with platinum agents and/or other DNA-damaging medications, including radiation; some of these patients had a prior history of more than one primary malignancy or bone marrow dysplasia. If prolonged hematologic toxicity occurs and blood counts do not recover to &le; grade 1 after 4 weeks, further evaluation (including bone marrow and cytogenetic analyses) is necessary. If MDS/AML is confirmed, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Monitor closely for toxicity in patients with mild or moderate renal impairment. Dosage adjustment is recommended for moderate impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dosage form selection: Olaparib is available as 100 mg and 150 mg tablets and as 50 mg capsules. Do not substitute the 50 mg capsules for the 100 mg or 150 mg tablets on a mg-per-mg basis due to differences in dosing and bioavailability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; BRCA-mutation status: Select patients for the treatment of advanced ovarian cancer or HER2-negative metastatic breast cancer based on the presence of deleterious or suspected deleterious BRCA-mutations. Information on approved tests for the detection of BRCA-mutations may be found at <a target=\"_blank\" href=\"http://www.fda.gov/companiondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ/rX/FBRnAtp+YOOMBGgh36vrA79ff4L/MZW&amp;TOPIC_ID=98761\" target=\"_blank\">http://www.fda.gov/companiondiagnostics</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26736588\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26736585\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=98761&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bitter Orange: May increase the serum concentration of Olaparib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Olaparib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Olaparib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Olaparib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Olaparib. Management: Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Olaparib. Management: Avoid use of strong CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853181\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Coadministration with grapefruit or Seville oranges may increase olaparib plasma concentrations. Management: Avoid concomitant administration with grapefruit, grapefruit juice, Seville oranges, or Seville orange juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853175\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies at doses less than human exposure. Based on animal reproduction studies and the mechanism of action, olaparib may be expected to cause adverse events to the fetus. Women of reproductive potential should use highly effective contraception during therapy and for at least 6 months after the last olaparib dose. In women of reproductive potential, pregnancy testing is recommended prior to treatment initiation. Males with female partners of reproductive potential or female partners who are pregnant should use effective contraception during treatment and for 3 months after the last olaparib dose; male patients also should not donate sperm during therapy and for 3 months following the last olaparib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853177\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if olaparib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that lactating women should not breastfeed during treatment and for 1 month after the last olaparib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853206\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit, grapefruit juice, Seville oranges, or Seville orange juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853209\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BRCA-mutation status (breast and advanced ovarian cancers); complete blood count at baseline and monthly thereafter, or as clinically indicated (weekly until recovery for prolonged hematologic toxicity), renal function, pregnancy test (prior to treatment initiation in women of reproductive potential); monitor for signs/symptoms of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) and pneumonitis. Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853183\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Olaparib is a poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, including PARP1, PARP2, and PARP3. PARP enzymes are involved in DNA transcription, cell cycle regulation, and DNA repair. Olaparib is a potent oral PARP inhibitor which induces synthetic lethality in BRCA1/2 deficient tumor cells through the formation of double-stranded DNA breaks which cannot be accurately repaired, which leads to disruption of cellular homeostasis and cell death (Ledermann 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26853186\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid; delayed with a high-fat meal (extent of absorption not significantly altered)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Capsule: 167 &plusmn; 196 L; Tablet: 158 &plusmn; 136 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~82%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic via CYP3A4; the majority of metabolism is through oxidation with some metabolites undergoing subsequent glucuronide or sulfate conjugation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Tablet formulation has higher bioavailability than the capsule formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination, terminal: Capsule: 11.9 &plusmn; 4.8 hours; Tablet: 14.9 &plusmn; 8.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Capsule: 1 to 3 hours; Tablet: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (44%, mostly metabolites); feces (42%, mostly metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26844485\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Lynparza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (112): $3,888.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lynparza Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $8,331.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $8,331.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26732987\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Linparza (UA);</li>\n      <li>Lyhnparza (FI);</li>\n      <li>Lynparza (AT, BB, CR, CZ, DE, DK, DO, EE, ES, FR, GB, GT, HK, HN, HR, HU, IE, IL, IS, KR, LT, LU, LV, MY, NI, NL, NO, PA, PL, PT, RO, SE, SI, SK, SV);</li>\n      <li>Lynparza Hard (SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. <i>Lancet</i>. 2010;376(9737):245-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/20609468/pubmed\" target=\"_blank\" id=\"20609468\">20609468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. <i>Gynecol Oncol</i>. 2016;140(2):199-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/26723501/pubmed\" target=\"_blank\" id=\"26723501\">26723501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Bohlke K, Lyman GH, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology focused guideline update. <i>J Clin Oncol</i>. 2016;34(4):381-386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/26527784/pubmed\" target=\"_blank\" id=\"26527784\">26527784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. <i>J Clin Oncol</i>. 2015;33(3):244-250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/25366685/pubmed\" target=\"_blank\" id=\"25366685\">25366685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. <i>J Clin Oncol</i>. 2012;30(4):372-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/22203755/pubmed\" target=\"_blank\" id=\"22203755\">22203755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. <i>N Engl J Med</i>. 2012;366(15):1382-1392.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/22452356/pubmed\" target=\"_blank\" id=\"22452356\">22452356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lynparza (olaparib) capsules [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lynparza (olaparib) capsules [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lynparza (olaparib) capsules [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lynparza (olaparib) tablets [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plummer R, Swaisland H, Leunen K, et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. <i>Cancer Chemother Pharmacol</i>. 2015;76(4):723-729.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/26242220/pubmed\" target=\"_blank\" id=\"26242220\">26242220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28578601\"></a>Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. <i>N Engl J Med</i>. 2017;377(6):523-533. doi: 10.1056/NEJMoa1706450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/28578601/pubmed\" target=\"_blank\" id=\"28578601\">28578601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol.</i> 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/olaparib-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 98761 Version 76.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26730986\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46780941\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F26641538\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26853200\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F26853201\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26853202\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26853203\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F26853204\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26730987\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26730985\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F26853157\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F26854741\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26853207\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133402\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F26641540\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26853154\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F26970623\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26641541\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26853178\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F26736588\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F26736585\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F26853181\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26853175\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F26853177\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F26853206\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26853209\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26853183\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F26853186\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26844485\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26732987\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/98761|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=olaparib-patient-drug-information\" class=\"drug drug_patient\">Olaparib: Patient drug information</a></li></ul></div></div>","javascript":null}